NDAORALSUSPENSION
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CARAFATE (sucralfate) by AbbVie is clinical pharmacology sucralfate is only minimally absorbed from the gastrointestinal tract. First approved in 1993.
Drug data last refreshed 19h ago · AI intelligence enriched 21h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARAFATE (sucralfate) is an oral aluminum complex suspension approved in 1993 for duodenal ulcer healing. It works through a local, non-systemic mechanism by forming an ulcer-adherent protective complex that shields the ulcer site from acid, pepsin, and bile salts. The drug is minimally absorbed and excreted primarily through urine.
$0.002BPart D
LOE ApproachingDeclining
Mature product in late-stage lifecycle with minimal claims volume ($2M Part D spend) signals a small, focused team managing a legacy brand facing generic erosion.
Mechanism of Action
CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be…
Pharmacologic Class:
Aluminum Complex
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CARAFATE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.